| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Second Regular National Report on the Implementation of the Cartagena Protocol on Biosafety
Record information and status
Record ID
102648
Status
Published
Date of creation
2011-10-31 20:03 UTC (andrew.bowers@cbd.int)
Date of publication
2011-10-31 20:03 UTC (andrew.bowers@cbd.int)

This document is also available in the following languages:
Origin of report
Country
  • Algeria
Contact officer for report
Coordinates
Latifa Benazza
Directrice de l'Environnement et du Développement durable
Ministère des Affaires étrangères
6, Promontoire des Anasser
Alger
Algeria
Phone:+213 21 50 43 18
Fax:+213 21 50 43 22
Email:BENAZZA@mae.dz
Consulted stakeholders
9. Organizations/stakeholders who were consulted or participated in the preparation of this report
FR
Ministère des Affaires étrangères
Ministère de l'Aménagement du Territoire et de l'Environnement
Ministère de l'Enseignement supérieur et de la Recherche scientifique
Ministère de la Santé, de la Population et de la Réforme hospitalière
Ministère de l'Agriculture et du Développement rural
Submission
10. Date of submission
2011-10-31
11. Time period covered by this report
Start date
2007-10-01
Time period covered by this report
End date
2011-09-30
Party to the Cartagena Protocol on Biosafety
12. Is your country a Party to the Cartagena Protocol on Biosafety (CPB)?
  • Yes
Article 2 – General provisions
15. Has your country introduced the necessary legal, administrative and other measures for the implementation of the Protocol?
  • A domestic regulatory framework is fully in place
16. Which specific instruments are in place for the implementation of your national biosafety framework?
  • One or more national biosafety regulations
17. Has your country established a mechanism for the budgetary allocations of funds for the operation of its national biosafety framework?
  • No
18. Does your country have permanent staff to administer functions directly related to the national biosafety framework?
  • No
20. Has your country’s biosafety framework / laws / regulations / guidelines been submitted to the Biosafety Clearing-House (BCH)?
  • Yes
21. Here you may provide further details on the implementation of Article 2 in your country:
FR
Concernant les lois nationales, un seul texte promulgué concerne les Organismes Génétiquement Modifiés sous forme d'arrêté du Ministère de l'Agriculture et du Développement Rural. Cet arrêté vise à titre conservatoire à éviter tout risque d'érosion génétique du patrimoine phytogénétique lié aux effets du flux génétique associés à l'utilisation d'un matériel végétal transgénique et à réunir les conditions techniques préalables à une production agricole naturelle (agriculture biologique).

Arrêté ministériel n°910 du 24 décembre 2000 interdisant l'importation, la production, la distribution, la commercialisation et l'utilisation du matériel végétal génétiquement modifié. Ce texte stipule que «l'importation, la distribution, la commercialisation et l'utilisation de matériel  végétal ayant fait l'objet d'un transfert artificiel de gène en provenance d'un autre individu appartenant à une espèce différente, voire d'un gène bactérien est interdite ». Par référence à l'article 13 de la loi 87-17 du 1er  août 1987, il est entendu par matériel végétal   « les plantes vivantes ou parties vivantes de plantes y compris les yeux, greffes, greffons, tubercules, rhizomes, boutures, pousses et semences, destinés à la multiplication ou à la reproduction ».
Article 6 – Transit and Contained use
25. Does your country regulate the transit of LMOs?
  • Yes
26. Does your country regulate the contained use of LMOs?
  • Yes
27. If you answered Yes to questions 25 or 26, has this information been submitted to the BCH?
  • Yes
28. Here you may provide further details on the implementation of Article 6 in your country:
FR
Pour ce qui est des importations, les importateurs de matériel végétal doivent fournir un certificat d'absence d'OGM dans les plantes et semences importées. Ce certificat est visé  par l'Institut National de la Protection des végétaux.

Une dérogation est donnée aux institutions scientifiques et aux structures de recherche qui peuvent, à des fins d'analyse et de recherche et sur leur demande, introduire, détenir, transporter et utiliser, sous des conditions préalablement définies, du matériel végétal génétiquement modifié.

La demande d'autorisation doit comporter impérativement :

- Nom, prénom et raison sociale du demandeur
- Nature du matériel végétal à introduire
- Objectif, lieu, conditions et durée de la manipulation ou de l'utilisation.    
Articles 7 to 10 – Advance Informed Agreement (AIA) and intentional introduction of LMOs into the environment
29. Has your country adopted law(s) / regulations / administrative measures for the operation of the AIA procedure of the Protocol?
  • No
30. Has your country adopted a domestic regulatory framework consistent with the Protocol regarding the transboundary movement of LMOs for intentional introduction into the environment?
  • No
31. Has your country established a mechanism for taking decisions regarding first intentional transboundary movements of LMOs for intentional introduction into the environment?
  • No
33. Has your country established a mechanism for monitoring potential effects of LMOs that are released into the environment?
  • No
34. Does your country have the capacity to detect and identify LMOs?
  • No
35. Has your country established legal requirements for exporters under its jurisdiction to notify in writing the competent national authority of the Party of import prior to the intentional transboundary movement of an LMO that falls within the scope of the AIA procedure?
  • No
36. Has your country established legal requirements for the accuracy of information contained in the notification?
  • No
37. Has your country ever received an application / notification regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
  • No
38. Has your country ever taken a decision on an application / notification regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
  • No
41. In the current reporting period, how many applications/notifications has your country received regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
  • None
42. In the current reporting period, how many decisions has your country taken regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
  • None
50. Here you may provide further details on the implementation of Articles 7-10 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs for intentional introduction to the environment:
FR
L'Algérie n'importe pas d'organismes vivants modifiés destinés à être introduits dans l'Environnement
Article 11 – Procedure for living modified organisms intended for direct use as food or feed, or for processing (LMOs-FFP)
51. Has your country adopted specific law(s) or regulation(s) for decision-making regarding domestic use, including placing on the market, of LMOs-FFP?
  • Yes
52. Has your country established legal requirements for the accuracy of information to be provided by the applicant?
  • No
53. Has your country established a mechanism to ensure that decisions regarding LMOs-FFP that may be subject to transboundary movement will be communicated to the Parties through the BCH?
  • No
54. Has your country established a mechanism for taking decisions on the import of LMOs-FFP?
  • No
55. Has your country declared through the BCH that in the absence of a regulatory framework its decisions prior to the first import of an LMO-FFP will be taken according to Article 11.6 of the Cartagena Protocol on Biosafety?
  • No
56. Has your country indicated its needs for financial and technical assistance and capacity building in respect of LMOs-FFP?
  • Yes
57. Has your country ever taken a decision on LMOs-FFP (either on import or domestic use)?
  • No
63. Here you may provide further details on the implementation of Article 11 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs-FFP:
FR
L'Algérie n'importe pas d'organismes vivants modifiés.

Dans le cadre du projet "développement d'un cadre national de biosécurité" un chapitre sur les besoins a été développé, à savoir, "Renforcement des capacités de contrôle".

Il urge pour la Partie algérienne que chaque secteur habilité mette en place son système de contrôle en s'appuyant sur les infrastructures et les moyens matériels et humains disponibles. Cet impératif est d'autant plus avéré pour ce qui concerne le système de contrôle des plants et des semences dans la mesure où le matériel végétal est interdit. Un laboratoire de contrôle devrait être mis en place rapidement. Ce laboratoire pourrait s'appuyer sur l'expertise de l'Institut National de la Recherche Agronomique ou sur l'Institut National Agronomique.

La création d'unités spécifiques au contrôle des OGM ne devrait pas constituer une tâche trop lourde. Un renforcement des capacités dans le domaine est à envisager sur les techniques et les standardisations des contrôles. Ce genre de formation est envisagé à l'avenir, dans certaines structures universitaires, comme à l'Institut National Agronomique où le Laboratoire de Phytopathologie et Biologie Moléculaire prépare une Convention avec le Laboratoire de détection des OGM de l'INRA de Versailles, lequel assure la coordination des laboratoires associés européens pour la détection et la traçabilité des OGM. Par ailleurs, il sera nécessaire d'acquérir les instruments d'analyse (Lecteur ELISA, PCR temps réel) nécessaires à l'évaluation et la gestion des risques.

Ces besoins ont été exprimés lors de la deuxième phase du projet PNUE-FEM, dès-lors que les décisions administratives et organisationnelles auront été prises.
Article 12 – Review of decision
64. Has your country established a mechanism for the review and change of a decision regarding an intentional transboundary movement of LMOs?
  • No
65. Has your country ever received a request for a review of a decision?
  • No
66. Has your country ever reviewed / changed a decision regarding an intentional transboundary movement of LMOs?
  • No
67. In the current reporting period, how many decisions were reviewed and/or changed regarding an intentional transboundary movement of an LMO?
  • None
71. Here you may provide further details on the implementation of Article 12 in your country:
FR
L'Algérie n'importe pas d'organismes vivants modifiés
Article 13 – Simplified procedure
72. Has your country established a system for the application of the simplified procedure regarding an intentional transboundary movement of LMOs?
  • No
73. Has your country ever applied the simplified procedure?
  • No
75. In the current reporting period, how many LMOs has your country applied the simplified procedure to?
  • None
76. Here you may provide further details on the implementation of Article 13 in your country:
FR
L'Algérie n'importe pas d'organismes vivants modifiés.
Article 14 – Bilateral, regional and multilateral agreements and arrangements
77. Has your country entered into any bilateral, regional or multilateral agreements or arrangements?
  • No
80. Here you may provide further details on the implementation of Article 14 in your country:
FR
L'Algérie n'a pas adhéré à des accords ou et des Arrangements bilatéraux, régionaux ou multilatéraux en lien avec l'esprit et la lettre du Prtocole de Cartagena
Article 15 – Risk assessment
81. Has your country established a mechanism for conducting risk assessments prior to taking decisions regarding LMOs?
  • No
83. Has your country established guidelines for how to conduct risk assessments prior to taking decisions regarding LMOs?
  • No
84. Has your country acquired the necessary domestic capacity to conduct risk assessment?
  • No
85. Has your country established a mechanism for training national experts to conduct risk assessments?
  • Yes
86. Has your country ever conducted a risk assessment of an LMO for intentional introduction into the environment?
  • No
87. Has your country ever conducted a risk assessment of an LMO intended for direct use as food or feed, or for processing?
  • No
88. If your country has taken decision(s) on LMOs for intentional introduction into the environment or on domestic use of LMOs-FFP, were risk assessments conducted for all decisions taken?
  • No
89. Has your country submitted summary reports of the risk assessments to the BCH?
  • No
90. In the current reporting period, if your country has taken decisions regarding LMOs, how many risk assessments were conducted in the context of these decisions?
  • None
91. Has your country ever required the exporter to conduct the risk assessment(s)?
  • No
92. Has your country ever required the notifier to bear the cost of the risk assessment(s) of LMOs?
  • No
93. Here you may provide further details on the implementation of Article 15 in your country:
FR
L'Algérie n'importe pas d'organismes vivants modifiés.
Article 16 – Risk management
94. Has your country established and maintained appropriate and operational mechanisms, measures and strategies to regulate, manage and control risks identified in risk assessments for:
94.1) LMOs for intentional introduction into the environment?
  • Yes
94.2) LMOs intended for direct use as food or feed, or for processing?
  • Yes
95. Has your country established and maintained appropriate measures to prevent unintentional transboundary movements of LMOs?
  • Yes
96. Has your country taken measures to ensure that any LMO, whether imported or locally developed, undergoes an appropriate period of observation that is commensurate with its life-cycle or generation time before it is put to its intended use?
  • Yes
97. Has your country cooperated with other Parties with a view to identifying LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity?
  • No
98. Has your country cooperated with other Parties with a view to taking measures regarding the treatment of LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity?
  • No
Article 17 – Unintentional transboundary movements and emergency measures
100. Has your country made available to the BCH the relevant details setting out its point of contact for the purposes of receiving notifications under Article 17?
  • No
101. Has your country established a mechanism for addressing emergency measures in case of unintentional transboundary movements of LMOs that are likely to have significant adverse effect on biological diversity?
  • No
102. Has your country implemented emergency measures in response to information about releases that led, or may have led, to unintentional transboundary movements of LMOs?
  • No
103. In the current reporting period, how many times has your country received information concerning occurrences that led, or may have led, to unintentional transboundary movement(s) of one or more LMOs to or from territories under its jurisdiction?
  • Never
107. Here you may provide further details on the implementation of Article 17 in your country:
FR
Durant la période couverte par le présent rapport, les Autorités algériennes habilitées par l'application des dispositions du Protocole de Cartagena n'ont pas relevé d'incidents apparents ayant pour résultat une libération entraînant un mouvement transfrontière non intentionnel.
Article 18 – Handling, transport, packaging and identification
108. Has your country taken measures to require that LMOs that are subject to transboundary movement are handled, packaged and transported under conditions of safety, taking into account relevant international rules and standards?
  • No
109. Has your country taken measures to require that documentation accompanying LMOs-FFP clearly identifies that, in cases where the identity of the LMOs is not known through means such as identity preservation systems, they may contain living modified organisms and are not intended for intentional introduction into the environment, as well as a contact point for further information?
  • No
110. Has your country taken measures to require that documentation accompanying LMOs-FFP clearly identifies that, in cases where the identity of the LMOs is known through means such as identity preservation systems, they contain living modified organisms and are not intended for intentional introduction into the environment, as well as a contact point for further information?
  • No
111. Has your country taken measures to require that documentation accompanying LMOs that are destined for contained use clearly identifies them as living modified organisms and specifies any requirements for the safe handling, storage, transport and use, the contact point for further information, including the name and address of the individual and institution to whom the LMO are consigned?
  • No
112. Has your country taken measures to require that documentation accompanying LMOs that are intended for intentional introduction into the environment of the Party of import, clearly identifies them as living modified organisms; specifies the identity and relevant traits and/or characteristics, any requirements for the safe handling, storage, transport and use, the contact point for further information and, as appropriate, the name and address of the importer and exporter; and contains a declaration that the movement is in conformity with the requirements of this Protocol applicable to the exporter?
  • No
113. Does your country have the capacity to enforce the requirements of identification and documentation of LMOs?
  • No
114. Has your country established procedures for the sampling and detection of LMOs?
  • No
Article 19 – Competent National Authorities and National Focal Points
116. Has your country designated one national focal point for the Cartagena Protocol to be responsible for liaison with the Secretariat?
  • Yes
117. Has your country designated one national focal point for the Biosafety Clearing-House to liaise with the Secretariat regarding issues of relevance to the development and implementation of the BCH?
  • Yes
118. Has your country designated one or more competent national authorities, which are responsible for performing the administrative functions required by the Cartagena Protocol on Biosafety and are authorized to act on your country’s behalf with respect to those functions?
  • No
120. Has your country made available the required information referred in questions 116-119 to the BCH?
  • Yes, all information
Article 20 – Information Sharing and the Biosafety Clearing-House (BCH)
124. Please provide an overview of the status of the information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH.
124.a) Existing national legislation, regulations and guidelines for implementing the Protocol, as well as information required by Parties for the advance informed agreement procedure (Article 20, paragraph 3 (a))
  • Information available and in the BCH
124.b) National laws, regulations and guidelines applicable to the import of LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 5)
  • Information not available
124.c) Bilateral, multilateral and regional agreements and arrangements (Articles 14, paragraph 2 and 20, paragraph 3 (b))
  • Information available and in the BCH
124.d) Contact details for competent national authorities (Article 19, paragraphs 2 and 3), national focal points (Article 19, paragraphs 1 and 3), and emergency contacts (Article 17, paragraph 3 (e))
  • Information available and in the BCH
124.e) Reports submitted by the Parties on the operation of the Protocol (Article 20, paragraph 3 (e))
  • Information available and in the BCH
124.f) Decisions by a Party on regulating the transit of specific living modified organisms (LMOs) (Article 6, paragraph 1)
  • Information not available
124.g) Occurrence of unintentional transboundary movements that are likely to have significant adverse effects on biological diversity (Article 17, paragraph 1)
  • Information not available
124.h) Illegal transboundary movements of LMOs (Article 25, paragraph 3)
  • Information not available
124.i) Final decisions regarding the importation or release of LMOs (i.e. approval or prohibition, any conditions, requests for further information, extensions granted, reasons for decision) (Articles 10, paragraph 3 and 20, paragraph 3(d))
  • Information available and in the BCH
124.j) Information on the application of domestic regulations to specific imports of LMOs (Article 14, paragraph 4)
  • Information available and in the BCH
124.k) Final decisions regarding the domestic use of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing (Article 11, paragraph 1)
  • Information available and in the BCH
124.l) Final decisions regarding the import of LMOs intended for direct use as food or feed, or for processing that are taken under domestic regulatory frameworks (Article 11, paragraph 4) or in accordance with annex III (Article 11, paragraph 6) (requirement of Article 20, paragraph 3(d))
  • Information available and in the BCH
124.m) Declarations regarding the framework to be used for LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 6)
  • Information available and in the BCH
124.n) Review and change of decisions regarding intentional transboundary movements of LMOs (Article 12, paragraph 1)
  • Information not available
124.o) LMOs granted exemption status by each Party (Article 13, paragraph 1)
  • Information available and in the BCH
124.p) Cases where intentional transboundary movement may take place at the same time as the movement is notified to the Party of import (Article 13, paragraph 1)
  • Information available and in the BCH
124.q) Summaries of risk assessments or environmental reviews of LMOs generated by regulatory processes and relevant information regarding products thereof (Article 20, paragraph 3 (c))
  • Information not available
125. Has your country established a mechanism for strengthening the capacity of the BCH National Focal Point to perform its administrative functions?
  • Yes
126. Has your country established a mechanism for the coordination among the BCH National Focal Point, the Cartagena Protocol focal point, and the competent national authority(ies) for making information available to the BCH?
  • No
127. Does your country use the information available in the BCH in its decision making processes on LMOs?
  • No
128. Has your country experienced difficulties accessing or using the BCH?
  • No
130. Is the information submitted by your country to the BCH complete and up-to date?
  • Yes
131. Here you may provide further details on the implementation of Article 20 in your country:
FR
Dans le cadre du projet PNUE-FEM, relatif au "Renforcement des Capacités en vue d'une Participation efficace au centre d'échange sur la biosécurité" (BCHI), un premier Atelier de sur "l'utilisation du Portail Central du Centre d'Echanges sur la "Prévention des risques biotechnologiques'' a été organisé, en novembre 2007, à Alger. Un second Atelier sur « l'utilisation du Portail Central du Centre d'Echanges sur la Prévention des risques biotechnologiques » a été organisé, en octobre 2008, à Alger.

Dans le cadre du projet BCHII, un premier atelier de formation sur « l'utilisation du Portail Central du Centre d'Echanges sur la Prévention des risques biotechnologiques  par les représentants du Gouvernement » a été organisé, du 12 au 14 juillet 2011, à Alger.
Article 21 – Confidential information
132. Has your country established procedures to protect confidential information received under the Protocol?
  • No
134. Here you may provide further details on the implementation of Article 21 in your country:
FR
L'Algérie n'importe pas d'organismes vivants modifiés.
Article 22 – Capacity-building
135. Has your country received external support or benefited from collaborative activities with other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety?
  • Yes
137. Has your country provided support to other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety?
  • No
139. Is your country eligible to receive funding from the Global Environment Facility (GEF)?
  • Yes
140. Has your country ever initiated a process to access GEF funds for building capacity in biosafety?
  • Yes
141. If you answered Yes to question 140, how would you characterize the process?
Please add further details about your experience in accessing GEF funds under question 150.
  • Average
142. Has your country ever received funding from the GEF for building capacity in biosafety?
  • Development of national biosafety frameworks
  • Building Capacity for Effective Participation in the BCH (Phase I)
  • Building Capacity for Effective Participation in the BCH (Phase II)
143. During the current reporting period, has your country undertaken activities for the development and/or strengthening of human resources and institutional capacities in biosafety?
  • Yes
144. If you answered Yes to question 143, in which of the following areas were these activities undertaken?
  • Public awareness, participation and education in biosafety
  • Information exchange and data management including participation in the Biosafety Clearing-House
145. During the current reporting period, has your country carried out a capacity-building needs assessment?
  • Yes
146. Does your country still have capacity-building needs?
  • Yes
147. If you answered Yes to question 146, indicate which of the following areas still need capacity-building.
  • Institutional capacity
  • Human resources capacity development and training
  • Risk management
  • Public awareness, participation and education in biosafety
  • Information exchange and data management including participation in the Biosafety Clearing-House
  • Scientific, technical and institutional collaboration at subregional, regional and international levels
  • Technology transfer
  • Identification of LMOs, including their detection
  • Socio-economic considerations
  • Handling of confidential information
  • Measures to address unintentional and/or illegal transboundary movements of LMOs
  • Scientific biosafety research relating to LMOs
  • Taking into account risks to human health
148. Has your country developed a capacity-building strategy or action plan?
  • No
149. Has your country submitted the details of national biosafety experts to the Roster of Experts in the BCH?
  • Yes
150. Here you may provide further details on the implementation of Article 22 in your country, including further details about your experience in accessing GEF funds:
FR
Dans le cadre du Projet PNUE-GEF sur le développement d'un cadre national de biosécurité, un Atelier sur "Les mécanismes d'évaluation et de gestion des risques" s'est tenu à Alger, les 15 et 16 juin 2004. Cet Atelier a regroupé une trentaine de participants provenant d'institutions et de structures de contrôle et de suivi, susceptibles de jouer, au niveau national, un rôle en matière de biosécurité.
Article 23 – Public awareness and participation
151. Has your country established a strategy or put in place legislation for promoting and facilitating public awareness, education and participation concerning the safe transfer, handling and use of LMOs?
  • No
152. Has your country established a biosafety website?
  • Yes
153. Has your country established a mechanism to ensure public access to information on living modified organisms that may be imported?
  • No
154. Has your country established a mechanism to consult the public in the decision-making process regarding LMOs?
  • No
155. Has your country established a mechanism to make available to the public the results of decisions taken on LMOs?
  • No
156. Has your country taken any initiative to inform its public about the means of public access to the Biosafety Clearing-House?
  • Yes
157. In the current reporting period, has your country promoted and facilitated public awareness, education and participation concerning the safe transfer, handling and use of LMOs?
  • No
159. In the current reporting period, how many times has your country consulted the public in the decision-making process regarding LMOs and made the results of such decisions available to the public?
  • None
160. Here you may provide further details on the implementation of Article 23 in your country:
FR
Dans le cadre du projet PNUE/FEM deux ateliers ont été organisés. Il s'agit de ce qui suit:

- un Atelier sur les mécanismes de participation du public au processus de biosécurité a été organisé, à Alger, le 29 juin 2004 pour une trentaine de participants. Les présentations se sont axées sur la connaissance des OGM, les systèmes réglementaires, administratifs de la gestion des OGM, la présentation du Projet de mise en place des cadres nationaux de biosécurité et les mécanismes de participation du public dans le Protocole de Biosécurité.

- un Atelier sur la participation du public au processus de biosécurité, organisé par l'Institut national d'Agronomie et l'Association AREA-ED, en décembre 2003. Des supports d'information sont élaborés sous forme de bulletins, brochures et de Site Web. Les informations diffusées concernent les législations internationales, régionales et nationales, les aspects scientifiques des biotechnologies et de la biosécurité, les études d'impacts sur l'environnement, la santé et les systèmes agraires, les relations avec les droits de propriété intellectuelle et l'appropriation du vivant et les enjeux économiques et sociaux

Aussi, dans le cadre du Projet PNUE/FEM:"Renforcement des capacités en vue d'une participation efficace au centre d'échange sur la biosécurité (BCH)", un Atelier national de sensibilisationsur le Centre national d'échange d'informations sur la biosécurité a été organisé, le 29 octobre 2008, à Alger.
Article 24 – Non-Parties
161. Has your country entered into any bilateral, regional, or multilateral agreement with non-Parties regarding transboundary movements of LMOs?
  • No
162. Has your country ever imported LMOs from a non-Party?
  • No
163. Has your country ever exported LMOs to a non-Party?
  • No
Article 25 – Illegal transboundary movements
168. Has your country adopted domestic measures aimed at preventing and/or penalizing transboundary movements of LMOs carried out in contravention of its domestic measures to implement this Protocol?
  • No
169. Has your country established a strategy for detecting illegal transboundary movements of LMOs?
  • No
170. In the current reporting period, how many times has your country received information concerning cases of illegal transboundary movements of an LMO to or from territories under its jurisdiction?
  • Never
Article 26 – Socio-economic considerations
176. If your country has taken a decision on import, has it ever taken into account socio-economic considerations arising from the impact of the LMO on the conservation and sustainable use of biological diversity?
  • No
177. Has your country cooperated with other Parties on research and information exchange on any socio-economic impacts of LMOs?
  • Yes, to a limited extent
Article 27 – Liability and Redress
179. Has your country signed the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress?
  • No
Article 33 – Monitoring and reporting
182. Has your country submitted the previous national reports (Interim and First National Reports)?
  • Yes, Interim report only
Other information
184. Please use this field to provide any other information on issues related to national implementation of the Protocol, including any obstacles or impediments encountered.
FR
Re; Q. 14 - l'Algérie a signé le Protocole de Cartagena sur la Prévention des risques biotechnologiques en mai 2000 et l'a ratifié, le 8 juin 2004, sur décret présidentiel 04-170